A Phase I Study Assessing the Safety of Immunotherapy with Standard Chemotherapy in Patients with Advanced Ovarian Cancer

Full Title

A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies

Purpose

AB928 is an investigational immunotherapy drug that reduces the ability of cancer cells to hide from the immune system. In this study, researchers want to find the highest dose of AB928 that can be given safely in combination with pegylated liposomal doxorubicin (PLD, a type of standard chemotherapy) in women with advanced ovarian cancer. AB928 is taken orally (by mouth) and PLD is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced ovarian cancer that persists despite prior treatment.
  • Patients should recover from the serious side effects of previous therapies before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for women age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Claire Friedman at 646-888-4247.

Protocol

19-132

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators